Stevenage Bioscience Catalyst announces Hugo Villanueva as Innovation and Business Development Director
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Dr Hugo Villanueva is to join as Innovation and Business Development Director in May 2020. Hugo joins us from...UK accounts for over 12% of global cell and gene therapy clinical trials
The UK and the NHS are providing the right environment and infrastructure to allow innovative cell and gene therapies to reach patients. International companies recognise the appeal of the UK cell and gene therapy ecosystem and are sponsoring the majority of the UK...KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814
~Phase 2b dose range finding study showed rapid and highly significant reductions in the frequency of hot flashes (primary endpoint) for the full 12-week treatment period~ ~Reduction in hot flashes was associated with statistically significant improvements in quality...Syncona makes a further $80 million commitment to Freeline
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces Syncona Ltd (Syncona) has made an $80.0 million (£61.1 million)[1] commitment in a Series C financing and has funded the first tranche of...£1.2m investment to reinforce Stevenage Campus as world class cell and gene therapy hub
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster. The £1.2m Local Growth Fund investment will provide much-needed temporary accommodation for growing...
